NCT06971900

GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria

A Phase 2a, Blinded, Randomized, Placebo-Controlled Study of PORT-77 Administered Orally to Adults With Erythropoietic Protoporphyria

• Status: Enrolling By Invitation
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 14 (estimated)
• Sponsor: Portal Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

A Phase 2a study of PORT-77 in adults with erythropoietic protoporphyria (EPP)

Conditions

• Erythropoietic Protoporphyria (EPP)

Interventions

Type	Name	Description
DRUG	PORT-77	Active oral dose form
DRUG	Placebo	Matching inactive oral dose form

Timeline

• Start date: 2025-04-04
• Primary completion: 2026-01-01
• Completion: 2026-01-01
• First posted: 2025-05-14
• Last updated: 2025-05-14

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study